These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30016475)

  • 21. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
    Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
    Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
    Imamura Y; Yanagihara K; Fukuda Y; Kaneko Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Sawa T; Wiener-Kronish JP; Kohno S
    Eur Respir J; 2007 May; 29(5):965-8. PubMed ID: 17301098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a multi-epitope vaccine candidate against
    Kalantari H; Habibi M; Ferdousi A; Asadi Karam MR; Mohammadian T
    J Biomol Struct Dyn; 2024 Aug; 42(12):6212-6227. PubMed ID: 37489041
    [No Abstract]   [Full Text] [Related]  

  • 24. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.
    Frank DW; Vallis A; Wiener-Kronish JP; Roy-Burman A; Spack EG; Mullaney BP; Megdoud M; Marks JD; Fritz R; Sawa T
    J Infect Dis; 2002 Jul; 186(1):64-73. PubMed ID: 12089663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.
    Shime N; Sawa T; Fujimoto J; Faure K; Allmond LR; Karaca T; Swanson BL; Spack EG; Wiener-Kronish JP
    J Immunol; 2001 Nov; 167(10):5880-6. PubMed ID: 11698464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial.
    Chastre J; François B; Bourgeois M; Komnos A; Ferrer R; Rahav G; De Schryver N; Lepape A; Koksal I; Luyt CE; Sánchez-García M; Torres A; Eggimann P; Koulenti D; Holland TL; Ali O; Shoemaker K; Ren P; Sauser J; Ruzin A; Tabor DE; Akhgar A; Wu Y; Jiang Y; DiGiandomenico A; Colbert S; Vandamme D; Coenjaerts F; Malhotra-Kumar S; Timbermont L; Oliver A; Barraud O; Bellamy T; Bonten M; Goossens H; Reisner C; Esser MT; Jafri HS;
    Crit Care; 2022 Nov; 26(1):355. PubMed ID: 36380312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa.
    Sato H; Hunt ML; Weiner JJ; Hansen AT; Frank DW
    PLoS One; 2011 Mar; 6(3):e18356. PubMed ID: 21479247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.
    Wang Q; Li H; Zhou J; Zhong M; Zhu D; Feng N; Liu F; Bai C; Song Y
    Respir Physiol Neurobiol; 2014 Mar; 193():21-8. PubMed ID: 24418353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein binding between PcrG-PcrV and PcrH-PopB/PopD encoded by the pcrGVH-popBD operon of the Pseudomonas aeruginosa type III secretion system.
    Allmond LR; Karaca TJ; Nguyen VN; Nguyen T; Wiener-Kronish JP; Sawa T
    Infect Immun; 2003 Apr; 71(4):2230-3. PubMed ID: 12654846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of Psl in the failure to eradicate Pseudomonas aeruginosa biofilms in children with cystic fibrosis.
    Morris AJ; Jackson L; Cw Yau Y; Reichhardt C; Beaudoin T; Uwumarenogie S; Guttman KM; Lynne Howell P; Parsek MR; Hoffman LR; Nguyen D; DiGiandomenico A; Guttman DS; Wozniak DJ; Waters VJ
    NPJ Biofilms Microbiomes; 2021 Aug; 7(1):63. PubMed ID: 34349133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. V-antigen genotype and phenotype analyses of clinical isolates of Pseudomonas aeruginosa.
    Allmond LR; Ajayi T; Moriyama K; Wiener-Kronish JP; Sawa T
    J Clin Microbiol; 2004 Aug; 42(8):3857-60. PubMed ID: 15297549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epitope mapping of monoclonal antibodies using synthetic oligosaccharides uncovers novel aspects of immune recognition of the Psl exopolysaccharide of Pseudomonas aeruginosa.
    Li H; Mo KF; Wang Q; Stover CK; DiGiandomenico A; Boons GJ
    Chemistry; 2013 Dec; 19(51):17425-31. PubMed ID: 24248772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An indirect enzyme-linked immunosorbent assay for rapid and quantitative assessment of Type III virulence phenotypes of Pseudomonas aeruginosa isolates.
    Li L; Ledizet M; Kar K; Koski RA; Kazmierczak BI
    Ann Clin Microbiol Antimicrob; 2005 Dec; 4():22. PubMed ID: 16375761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Biofilm Formation, Psl Exopolysaccharide Expression, and Clinical Outcomes in Pseudomonas aeruginosa Keratitis: Analysis of Isolates in the Steroids for Corneal Ulcers Trial.
    Zegans ME; DiGiandomenico A; Ray K; Naimie A; Keller AE; Stover CK; Lalitha P; Srinivasan M; Acharya NR; Lietman TM
    JAMA Ophthalmol; 2016 Apr; 134(4):383-9. PubMed ID: 26846404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.
    Neely AN; Holder IA; Wiener-Kronish JP; Sawa T
    Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.
    Hamaoka S; Naito Y; Katoh H; Shimizu M; Kinoshita M; Akiyama K; Kainuma A; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2017 Feb; 61(2):64-74. PubMed ID: 28370521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement.
    De Tavernier E; Detalle L; Morizzo E; Roobrouck A; De Taeye S; Rieger M; Verhaeghe T; Correia A; Van Hegelsom R; Figueirido R; Noens J; Steffensen S; Stöhr T; Van de Velde W; Depla E; Dombrecht B
    J Biol Chem; 2016 Jul; 291(29):15243-55. PubMed ID: 27226529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.
    DiGiandomenico A; Warrener P; Hamilton M; Guillard S; Ravn P; Minter R; Camara MM; Venkatraman V; Macgill RS; Lin J; Wang Q; Keller AE; Bonnell JC; Tomich M; Jermutus L; McCarthy MP; Melnick DA; Suzich JA; Stover CK
    J Exp Med; 2012 Jul; 209(7):1273-87. PubMed ID: 22734046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against
    Wan C; Zhang J; Zhao L; Cheng X; Gao C; Wang Y; Xu W; Zou Q; Gu J
    Front Immunol; 2019; 10():781. PubMed ID: 31068928
    [No Abstract]   [Full Text] [Related]  

  • 40. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.